| Stereochemistry | RACEMIC |
| Molecular Formula | C13H16N4O6 |
| Molecular Weight | 324.2893 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+](=O)C1=CC=C(O1)\C=N\N2CC(CN3CCOCC3)OC2=O
InChI
InChIKey=YVQVOQKFMFRVGR-VGOFMYFVSA-N
InChI=1S/C13H16N4O6/c18-13-16(14-7-10-1-2-12(22-10)17(19)20)9-11(23-13)8-15-3-5-21-6-4-15/h1-2,7,11H,3-6,8-9H2/b14-7+
| Molecular Formula | C13H16N4O6 |
| Molecular Weight | 324.2893 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Optical Activity | ( + / - ) |
Furaltadone is a veterinary product, which is marketed for the treatment and control of salmonella infection of poultry. In 1960th was investigated the antibacterial properties of this drug against human Rhodesian sleeping sickness. In three cases treated, two were apparently curated and the third relapsed. No toxic effects attributable to the product had been observed. However, the further investigation of the furaltadone in human was not provided.
Approval Year
Sourcing
PubMed
Patents
|
|
SALT/SOLVATE -> PARENT | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 3 of 3 entries
